Pharvaris shares jumped up to 20% after its oral HAE drug deucrictibant delivered positive Phase 3 results in the RAPIDe-3 trial, the company’s first study for on-demand treatment of hereditary angioedema attacks. The data will support marketing submissions in early 2026. PHVS became a top Stocktwits trender, with retail sentiment turning extremely bullish.